These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Synthesis and preclinical evaluation of the 177Lu-DOTA-PSMA(inhibitor)-Lys3-bombesin heterodimer designed as a radiotheranostic probe for prostate cancer. Escudero-Castellanos A; Ocampo-García B; Ferro-Flores G; Santos-Cuevas C; Morales-Ávila E; Luna-Gutiérrez M; Isaac-Olivé K Nucl Med Commun; 2019 Mar; 40(3):278-286. PubMed ID: 30763290 [TBL] [Abstract][Full Text] [Related]
7. Clinical Translation of a Dual Integrin αvβ3- and Gastrin-Releasing Peptide Receptor-Targeting PET Radiotracer, 68Ga-BBN-RGD. Zhang J; Niu G; Lang L; Li F; Fan X; Yan X; Yao S; Yan W; Huo L; Chen L; Li Z; Zhu Z; Chen X J Nucl Med; 2017 Feb; 58(2):228-234. PubMed ID: 27493267 [TBL] [Abstract][Full Text] [Related]
8. PET Using a GRPR Antagonist Zhang J; Niu G; Fan X; Lang L; Hou G; Chen L; Wu H; Zhu Z; Li F; Chen X J Nucl Med; 2018 Jun; 59(6):922-928. PubMed ID: 29123014 [TBL] [Abstract][Full Text] [Related]
9. The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions. Afshar-Oromieh A; Hetzheim H; Kratochwil C; Benesova M; Eder M; Neels OC; Eisenhut M; Kübler W; Holland-Letz T; Giesel FL; Mier W; Kopka K; Haberkorn U J Nucl Med; 2015 Nov; 56(11):1697-705. PubMed ID: 26294298 [TBL] [Abstract][Full Text] [Related]
10. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist. Zhang H; Desai P; Koike Y; Houghton J; Carlin S; Tandon N; Touijer K; Weber WA J Nucl Med; 2017 Jan; 58(1):29-35. PubMed ID: 27516447 [TBL] [Abstract][Full Text] [Related]
11. 68Ga-NOTA-Aca-BBN(7-14) PET/CT in Healthy Volunteers and Glioma Patients. Zhang J; Li D; Lang L; Zhu Z; Wang L; Wu P; Niu G; Li F; Chen X J Nucl Med; 2016 Jan; 57(1):9-14. PubMed ID: 26449838 [TBL] [Abstract][Full Text] [Related]
12. Targeted imaging of gastrin-releasing peptide receptors with 99mTc-EDDA/HYNIC-[Lys3]-bombesin: biokinetics and dosimetry in women. Santos-Cuevas CL; Ferro-Flores G; Arteaga de Murphy C; Pichardo-Romero PA Nucl Med Commun; 2008 Aug; 29(8):741-7. PubMed ID: 18753829 [TBL] [Abstract][Full Text] [Related]
13. Clinical Translation and First In-Human Use of [ Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832 [TBL] [Abstract][Full Text] [Related]
14. MITIGATE-NeoBOMB1, a Phase I/IIa Study to Evaluate Safety, Pharmacokinetics, and Preliminary Imaging of Gruber L; Jiménez-Franco LD; Decristoforo C; Uprimny C; Glatting G; Hohenberger P; Schoenberg SO; Reindl W; Orlandi F; Mariani M; Jaschke W; Virgolini I J Nucl Med; 2020 Dec; 61(12):1749-1755. PubMed ID: 32332143 [TBL] [Abstract][Full Text] [Related]
15. Receptor-binding, biodistribution, dosimetry, and micro-SPECT/CT imaging of 111In-[DTPA(1), Lys(3), Tyr(4)]-bombesin analog in human prostate tumor-bearing mice. Ho CL; Chen LC; Lee WC; Chiu SP; Hsu WC; Wu YH; Yeh CH; Stabin MG; Jan ML; Lin WJ; Lee TW; Chang CH Cancer Biother Radiopharm; 2009 Aug; 24(4):435-43. PubMed ID: 19694578 [TBL] [Abstract][Full Text] [Related]
16. Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [⁶⁸Ga]SB3 and PET/CT. Maina T; Bergsma H; Kulkarni HR; Mueller D; Charalambidis D; Krenning EP; Nock BA; de Jong M; Baum RP Eur J Nucl Med Mol Imaging; 2016 May; 43(5):964-973. PubMed ID: 26631238 [TBL] [Abstract][Full Text] [Related]
17. Investigation of Tumor Cells and Receptor-Ligand Simulation Models for the Development of PET Imaging Probes Targeting PSMA and GRPR and a Possible Crosstalk between the Two Receptors. Liolios C; Patsis C; Lambrinidis G; Tzortzini E; Roscher M; Bauder-Wüst U; Kolocouris A; Kopka K Mol Pharm; 2022 Jul; 19(7):2231-2247. PubMed ID: 35467350 [TBL] [Abstract][Full Text] [Related]
18. Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of Hofman MS; Eu P; Jackson P; Hong E; Binns D; Iravani A; Murphy D; Mitchell C; Siva S; Hicks RJ; Young JD; Blower PJ; Mullen GE J Nucl Med; 2018 Apr; 59(4):625-631. PubMed ID: 28986512 [No Abstract] [Full Text] [Related]